Karen Uhlmann
Founder at OMEICOS Therapeutics GmbH
Profile
Karen Uhlmann is the founder.
She founded OMEICOS Therapeutics GmbH in 2013 and holds the title of Vice President-Operations & IP.
Dr. Uhlmann has a graduate degree from Freie Universität Berlin and a doctorate degree from Humboldt-Universität zu Berlin.
Karen Uhlmann active positions
| Companies | Position | Start |
|---|---|---|
OMEICOS Therapeutics GmbH
 OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Founder | 01/01/2013 |
Training of Karen Uhlmann
| Freie Universität Berlin | Graduate Degree |
| Humboldt-Universität zu Berlin | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
- Stock Market
- Insiders
- Karen Uhlmann
